Amgen Inc

詳細情報 Amgen Inc 企業名

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

企業情報

企業コードAMGN

会社名Amgen Inc

上場日Jun 17, 1983

設立日1986

最高経営責任者「CEO」Mr. Robert A. (Bob) Bradway

従業員数28000

証券種類Ordinary Share

決算期末Jun 17

本社所在地One Amgen Center Drive

都市THOUSAND OAKS

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号91320-1799

電話番号18054471000

ウェブサイトhttps://www.amgen.com/

企業コードAMGN

上場日Jun 17, 1983

設立日1986

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

Dr. Brian J. Druker, M.D.

Independent Director

7.57K

+11.97%

Dr. Wanda M. Austin, Ph.D.

Independent Director

7.35K

+12.36%

Ms. Nancy A. Grygiel

Senior Vice President, Chief Compliance Officer

7.30K

+5.21%

Ms. Amy E. Miles

Independent Director

4.84K

+20.06%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

Other

3.67B

45.05%

地域別USD

会社名

収益

比率

US

5.34B

65.55%

ROW

2.09B

25.64%

事業別

地域別

事業別USD

会社名

収益

比率

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

Other

3.67B

45.05%

株主

更新時刻: Fri, May 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.79%

State Street Global Advisors (US)

5.43%

BlackRock Institutional Trust Company, N.A.

5.30%

Capital World Investors

3.11%

Capital International Investors

2.81%

Other

73.56%

株主統計

比率

The Vanguard Group, Inc.

9.79%

State Street Global Advisors (US)

5.43%

BlackRock Institutional Trust Company, N.A.

5.30%

Capital World Investors

3.11%

Capital International Investors

2.81%

Other

73.56%

種類

株主統計

比率

Investment Advisor

42.51%

Investment Advisor/Hedge Fund

29.29%

Research Firm

4.94%

Pension Fund

2.21%

Bank and Trust

1.91%

Sovereign Wealth Fund

1.20%

Hedge Fund

0.91%

Insurance Company

0.63%

Individual Investor

0.17%

Other

16.22%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

4414

451.29M

83.92%

+4.49M

2025Q1

4519

453.49M

84.33%

+5.91M

2024Q4

4466

443.40M

82.54%

+89.78K

2024Q3

4316

438.01M

81.42%

-5.13M

2024Q2

4284

437.79M

81.61%

-4.94M

2024Q1

4192

436.25M

81.40%

-5.11M

2023Q4

4150

435.28M

81.36%

+42.25K

2023Q3

3990

429.94M

80.36%

-4.48M

2023Q2

3936

426.14M

79.65%

-4.34M

2023Q1

3951

427.29M

80.00%

-4.36M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

52.63M

9.79%

+145.69K

+0.28%

Mar 31, 2025

State Street Global Advisors (US)

29.18M

5.43%

-254.42K

-0.86%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

28.50M

5.3%

-289.51K

-1.01%

Mar 31, 2025

Capital World Investors

16.70M

3.11%

+10.21M

+157.12%

Mar 31, 2025

Capital International Investors

15.13M

2.81%

+2.92M

+23.93%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.73M

2.37%

+252.31K

+2.02%

Mar 31, 2025

PRIMECAP Management Company

12.39M

2.3%

-613.83K

-4.72%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

12.21M

2.27%

-999.66K

-7.57%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

11.11M

2.07%

-33.38K

-0.30%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

8.73M

1.62%

+352.70K

+4.21%

Mar 31, 2025

詳細を見る

関連ETF

更新時刻: Sun, Jul 6

銘柄名

比率

VanEck Biotech ETF

16.62%

FT Vest DJIA Dogs 10 Target Income ETF

9.94%

Invesco Nasdaq Biotechnology ETF

8.43%

ProShares Ultra Nasdaq Biotechnology

7.64%

iShares Biotechnology ETF

7.59%

Invesco Dow Jones Industrial Average Dividend ETF

5.11%

Invesco Pharmaceuticals ETF

5%

Invesco Biotechnology & Genome ETF

4.86%

Proshares Ultra DOW 30

4.19%

Global X Dow 30 Covered Call ETF

4.19%

詳細を見る

VanEck Biotech ETF

比率16.62%

FT Vest DJIA Dogs 10 Target Income ETF

比率9.94%

Invesco Nasdaq Biotechnology ETF

比率8.43%

ProShares Ultra Nasdaq Biotechnology

比率7.64%

iShares Biotechnology ETF

比率7.59%

Invesco Dow Jones Industrial Average Dividend ETF

比率5.11%

Invesco Pharmaceuticals ETF

比率5%

Invesco Biotechnology & Genome ETF

比率4.86%

Proshares Ultra DOW 30

比率4.19%

Global X Dow 30 Covered Call ETF

比率4.19%

配当金

過去5年間の配当金総支払額は 21.35B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Dec 10, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 07, 2025

Feb 14, 2025

Oct 25, 2024

AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024

Nov 18, 2024

Dec 09, 2024

Nov 18, 2024

Aug 02, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 06, 2024

Aug 16, 2024

Mar 06, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024

May 17, 2024

Jun 07, 2024

May 16, 2024

Dec 12, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024

Feb 16, 2024

Mar 07, 2024

Feb 15, 2024

Oct 24, 2023

AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023

Nov 17, 2023

Dec 08, 2023

Nov 16, 2023

Aug 01, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 08, 2023

Aug 17, 2023

Mar 07, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023

May 18, 2023

Jun 08, 2023

May 17, 2023

Dec 12, 2022

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 08, 2023

Feb 14, 2023

Oct 28, 2022

AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022

Nov 17, 2022

Dec 08, 2022

Nov 16, 2022

詳細を見る

株式分割

日付

種類

比率

データなし

日付

種類

比率

データなし

298.560USD

Amgen Inc

298.560

概要

企業名